Lancet Subsidon: Paborizumab can significantly improve the disease-free survival period of the IB-IIIA phase NSCLC patients with a tumor.
*For medical professionals for reading reference1 minute every day, give you the p...
*For medical professionals for reading reference1 minute every day, give you the p...